Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Euronext Paris
07:02:10 2026-09-08 am EDT
|
5-day change | 1st Jan Change | ||
| 71.12 EUR | -0.67% |
|
-0.61% | +13.97% |
| Aug. 24 | Wall Street's Three-Way Stress Test |  |
| Jul. 23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 |
| Market Cap | 12.43B 14.45B 11.69B 10.67B 19.96B 1,367B 20.02B 139B 53.58B 700B 54.28B 53.09B 2,230B | P/E 2026 * |
23.9x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 15.78B 18.35B 14.84B 13.55B 25.34B 1,735B 25.42B 176B 68.02B 889B 68.9B 67.4B 2,830B | EV / Sales 2026 * |
2.08x | EV / Sales 2027 * | 1.93x |
| Free-Float |
60.39% | Yield 2026 * |
1.13% | Yield 2027 * | 1.28% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Xetra
| ESF0 | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript : Eurofins Scientific SE
| 1 day | -0.34% | ||
| 1 week | -0.28% | ||
| Current month | -1.63% | ||
| 1 month | +1.88% | ||
| 3 months | +9.99% | ||
| 6 months | +12.34% | ||
| Current year | +14.36% |
| 1 week | 68.38 |  | 74.78 |
| 1 month | 68.38 | | 74.78 |
| Current year | 56.84 | | 74.78 |
| 1 year | 54.86 | | 74.78 |
| 3 years | 39.47 | | 74.78 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.34% | -0.28% | +11.64% | +31.71% | 14.45B | |
| -0.20% | -3.29% | -2.00% | +15.50% | 48.41B | |
| -0.40% | +2.16% | +418.57% | +554.47% | 45.01B | |
| -1.42% | +2.52% | +42.67% | +22.27% | 44.07B | |
| -1.22% | -0.37% | +4.82% | +84.42% | 40.73B | |
| -0.96% | -1.38% | +15.75% | +45.91% | 33.21B | |
| -0.21% | +2.86% | - | - | 17.77B | |
| -0.35% | -0.45% | +21.42% | +117.63% | 16.5B | |
| -1.65% | +0.09% | +75.93% | +41.15% | 13.77B | |
| +0.78% | -0.08% | -5.74% | -36.13% | 12.72B | |
| Average | -0.60% | -0.04% | +64.78% | +97.44% | 28.67B | |
| Weighted average by Cap. | -0.70% | -0.16% | +84.94% | +127.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.59B 8.82B 7.14B 6.51B 12.18B 834B 12.22B 84.62B 32.71B 427B 33.14B 32.41B 1,361B | 8.01B 9.31B 7.53B 6.88B 12.86B 881B 12.9B 89.32B 34.53B 451B 34.98B 34.21B 1,437B |
| Net income | 531M 617M 499M 456M 853M 58.38B 855M 5.92B 2.29B 29.9B 2.32B 2.27B 95.24B | 660M 767M 620M 566M 1.06B 72.55B 1.06B 7.36B 2.84B 37.15B 2.88B 2.82B 118B |
| Net Debt | 3.35B 3.89B 3.15B 2.88B 5.38B 368B 5.4B 37.35B 14.44B 189B 14.62B 14.3B 601B | 3.01B 3.5B 2.83B 2.59B 4.84B 331B 4.85B 33.61B 12.99B 170B 13.16B 12.87B 541B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-08 | €71.12 | -0.67% | 79,320 |
| 26-09-07 | €71.60 | -1.54% | 146,380 |
| 26-09-04 | €72.72 | -1.01% | 167,941 |
| 26-09-03 | €73.46 | +0.93% | 307,393 |
| 26-09-02 | €72.78 | +1.70% | 228,096 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
